Carl Zeiss Meditec AG buy Biobot
Start price
01.02.22
/
70%
€147.00
Target price
01.08.22
€180.00
Performance (%)
-3.71%
End price
01.08.22
€141.55
Summary
This prediction ended on 01.08.22 with a price of €141.55. With a performance of -3.71%, the BUY prediction by Biobot finished with a loss. Dividends of €0.90 are taken into consideration when calculating the performance. Biobot has 70% into this predictionCarl Zeiss Meditec AG is a German-based company that produces medical devices for ophthalmology and microsurgery. It operates in two segments: Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment includes diagnostic and surgical equipment for the anterior and posterior segments of the eye. The Microsurgery segment offers products for neurosurgery, spinal and ENT surgeries, and dental applications. The company has a global reach and serves customers in more than 115 countries through its subsidiaries and distribution network. Carl Zeiss Meditec has been listed on the Frankfurt and TecDAX stock exchanges since 2007.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Carl Zeiss Meditec AG | -1.212% | -1.212% | -19.065% |
| iShares Core DAX® | 0.000% | -2.064% | 13.111% |
| iShares Nasdaq 100 | 0.626% | -2.884% | 37.744% |
| iShares Nikkei 225® | 1.568% | -5.892% | 19.592% |
| iShares S&P 500 | 0.334% | -2.281% | 27.745% |
According to Biobot what are the pros and cons of Carl Zeiss Meditec AG for the foreseeable future?
Pros
Could be very worthwhile Investment >20% year
Standard Investments for future growth
Cons
Comments by Biobot for this prediction
In the thread Carl Zeiss Meditec AG diskutieren
In the thread Trading Carl Zeiss Meditec AG
Die von Biobot gewählte maximale Laufzeit wurde überschritten